Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer (SABR-ROC)

  • STATUS
    Recruiting
  • End date
    Dec 25, 2026
  • participants needed
    270
  • sponsor
    Yonsei University
Updated on 4 October 2022

Summary

Rationale Ovarian cancer is the 3rd most common gynecologic malignancy in Korea. The standard treatment is tumor debulking surgery with or without adjuvant chemotherapy. However, with a recurrence rate of 80%, the treatment results are the worst among gynecological cancers. The use of target and immune agents have demonstrated to improve survival. However, long-term maintenance of systemic therapy is often difficult because recurrent tumors do not respond uniformly to systemic therapy.

In the 1980~1990s, whole abdomen irradiation had been tried and faded out owing to many side effects with the introduction of taxane. Efforts have been made to find the role of salvage radiation therapy (RT) in recurrent ovarian cancer. Involved field radiotherapy (IFRT) emerged to cover the gross tumor plus regional microscopic disease in addition to salvage chemotherapy. It showed high local control, provided chemotherapy holiday in selected cases, but did not prevent out-field progression. Stereotactic ABlative Radiotherapy (SABR) is the latest treatment using an intensity modulated technique to increase the fractional dose, reduces the number of treatments, and destroys the tumor with high accuracy. SABR-COMET study, a representative clinical study, showed a significant increase in overall survival in solid cancers.

Objectives The primary objective; to evaluate whether the addition of SABR to standard salvage treatment significantly improves 3-year overall survival (OS) in patients with recurrent ovarian cancer.

The secondary objectives;

  • to check whether it significantly affects quality of life (Health-related QoL), patient-reported outcome (PRO)
  • to develop an deep learning-based predictive model for the treatment response of ovarian cancer subjects using radiomic and genomic analysis.

Study design Arm 1; Standard salvage therapy Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.

Arm 2; Standard salvage therapy+ SABR Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.

Stratification factors

  1. The number of No ascites, Platinum-sensitive, Normal CA125 and ECOG0-1; 0~3 vs. 4
  2. Location of the lesion; Lymph node lesion vs. Non-lymph node lesion
  3. PARP inhibitor; Used vs. Not used

Randomization Arm 1 : Arm 2 = 1 : 2

Estimated Accrual :

  • The sample size 270 was calculated by setting the sample size to a Type I error rate (α) of 0.05 and Statistical Power of 80% using 2-Sided Equity and log-rank test.
  • Accurate time: 2 years, Follow-up: 3 years (total 5 years)
  • Alpha = 0.05, Power = 80%
  • 1 year drop-out: 5% per group
  • 3 year survival proportion: RT group 74.42%, No RT group 58%
  • Arm 1: Arm 2 = 1 : 2 ratio

Description

Treatment Plan Arm 2; SABR Number of Fractions Preferred Doses Acceptable Doses

1 20 Gy 16-24 Gy 3 30 Gy 24-33 Gy 5 35 Gy 25-40 Gy 10 40 Gy 35-45 Gy

Patient Evaluation:

  • Interviews
  • It was performed 3, 6, 9, 12, 18, 24, 30, and 36 months after the end of treatment.
  • Medical history listening, physical examination and assessment of all possible side effects
  • The relevant examination can be prescribed if necessary.
  • Imaging examination
  • one of CT or PET-CT including areas suspected of recurrence or treatment is possible.
  • If PET-CT was not performed within two months before treatment, it is recommended to perform PET-CT before treatment NOTE: Before treatment, it is recommended to perform the same examination as the imaging test that evaluated the treatment site.
  • Tumor marker CA125 examination: performed on every visit after radiation therapy.
  • Survey EORTC-QLQ-C30 questionnaire; prior to radiation therapy, 12, 24, and 36 months after treatment FACIT-TS-G (Arm 2 subjects); before radiation therapy, 12, 24, and 36 months after treatment.

Details
Condition Recurrent Epithelial Ovarian Cancer
Treatment Standard salvage therapy, Standard salvage therapy + SABR
Clinical Study IdentifierNCT05444270
SponsorYonsei University
Last Modified on4 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Pathologically confirmed epithelial ovarian cancer
Should have completed standard treatment for the primary tumor initially. (In the case of advanced ovarian cancer, maximal debulking operation and adjuvant platinum-based chemotherapy are performed according to the stage)
Number if recurred site allowed; within 10
Maximum diameter of each metastasis site of gross tumor ≤ 5 cm
Age ≥ 19 year old
Sufficient bone marrow function on tests performed within 60 days prior to study enrollment, including
Absolute neutrophil count (ANC) ≥ 500 / mm3
Platelet ≥ 50,000 / mm3
Hb ≥ 8.0 g / dl (Treatments such as blood transfusions to maintain hemoglobin count are permitted)
Zubrod daily living performance ≤ 2 within 60 days prior to study enrollment
Subjects must submit research-related informed consent prior to participation in the study

Exclusion Criteria

Brain metastasis
Diffuse peritoneal carcinomatosis
Exudative, hematological, or cytologically proven malignant exudate (Malignant pleural effusion)
If previously treated with radiation therapy to metastases
When targeting is difficult because the boundary of the metastasis site is not clear
Coexisting or previous invasive cancer (excluding Thyroid cancer, Cervix CIS, basal cell carcinoma of skin, early gastric cancer) has not been disease-free for more than 3 years
Pregnancy
Serious comorbidities defined as below
Unstable angina or congestive heart failure requiring hospitalization within the last 6 months
Deep myocardial infarction within the last 6 months
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of enrollment
At the time of enrollment, exacerbation of chronic obstructive pulmonary disease or other respiratory disease that requires hospitalization or makes it difficult to proceed with treatment in this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note